1. The use of dexanabinol or its derivative for cancer apoptosis in a patient where the cancer cells are selected from one or more of the following: primary cancer, breast cancer, colon cancer, prostate cancer, non-small cell lung cancer, glioblastoma, lymphoma, mesothelioma, cancer liver, intrahepatic bile duct cancer, esophageal cancer, pancreatic cancer, stomach cancer, laryngeal cancer, brain cancer, ovarian cancer, testicular cancer, cervical cancer, oral cancer, pharyngeal cancer, kidney cancer, thyroid cancer, uterine cancer, urinary cancer bladder, hepatocellular carcinoma, thyroid carcinoma, osteosarcoma, small cell lung cancer, leukemia, myeloma, gastric carcinoma and metastatic cancer. 2. The use of claim 1, wherein the cancer cells are selected from one or more of the following: primary cancer, breast cancer, colon cancer, prostate cancer, non-small cell lung cancer, glioblastoma, lymphoma, and metastatic cancer. The use according to claim 1, which provides for the use of a therapeutically effective amount of dexanabinol or its derivative sufficient to inhibit tumorigenesis of a cancer cell. The use according to claim 1 in combination with another therapeutic agent for the treatment of cancer. The use of claim 4, wherein another therapeutic agent for treating cancer is useful for inhibiting tumorigenesis, inhibiting cell proliferation, or inducing cytotoxicity. The use according to claim 1, wherein the cancer to be treated can be precancerous, malignant, metastatic or multidrug-resistant, and combinations thereof. The use of claim 6, wherein the cancer1. Применение дексанабинола или его производного для апоптоза рака у пациента, где раковые клетки выбраны из одного или более из следующих: первичный рак, рак молочной железы, рак толстой кишки, рак предстательной железы, немелкоклеточный рак легкого, глиобластома, лимфома, мезотелиома, рак печени, рак внутрипеченочного желчного протока, рак пищевода, рак поджелудочной железы, рак желудка, рак гортани, рак
